EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

An orally available Ca v 2.2 calcium channel inhibitor for the treatment of neuropathic pain

Janine Kutzsche, Gustavo A Guzman, Antje Willuweit, Olaf Kletke, Esther Wollert, Ian Gering, Dagmar Jürgens, Jörg Breitkreutz, Holger Stark iD, Annette G Beck-Sickinger, Nikolaj Klöcker, Patricia Hidalgo und 1 weitere

British Journal of Pharmacology · 2024-06 · 181 (12) · 1734-1756

DOI: 10.1111/bph.16309 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 07.02.2024. Verfasst von Janine Kutzsche und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biological Information Processing 7, Structural Biochemistry, Forschungszentrum Jülich GmbH, Jülich, Germany. Hauptthemen laut MEDLINE: Calcium Channel Blockers, Calcium Channels, N-Type, Neuralgia. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Forschungszentrum Jülich, Helmholtz Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Neuropathic pain affects up to 10% of the global population and is caused by an injury or a disease affecting the somatosensory, peripheral, or central nervous system. NP is characterized by chronic, severe and opioid‐resistant properties. Therefore, its clinical management remains very challenging. The N‐type voltage‐gated calcium channel, Ca v 2.2, is a validated target for therapeutic intervention in chronic and neuropathic pain. The conotoxin ziconotide (Prialt®) is an FDA‐approved drug that blocks Ca v 2.2 channel but needs to be administered intrathecally. Thus, although being principally efficient, the required application route is very much in disfavour. Experimental Approach and Key Results Here, we describe an orally available drug candidate, RD2, which competes with ziconotide binding to Ca v 2.2 at nanomolar concentrations and inhibits Ca v 2.2 almost completely reversible. Other voltage‐gated calcium channel subtypes, like Ca v 1.2 and Ca v 3.2, were affected by RD2 only at concentrations higher than 10 μM. Data from sciatic inflammatory neuritis rat model demonstrated the in vivo proof of concept, as low‐dose RD2 (5 mg·kg ‐1 ) administered orally alleviated neuropathic pain compared with vehicle controls. High‐dose RD2 (50 mg·kg ‐1 ) was necessary to reduce pain sensation in acute thermal response assessed by the tail flick test. Conclusions and Implications Taken together, these results demonstrate that RD2 has antiallodynic properties. RD2 is orally available, which is the most convenient application form for patients and caregivers. The surprising and novel result from standard receptor screens opens the room for further optimization into new promising drug candidates, which address an unmet medical need.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Calcium Channel BlockersCalcium Channels, N-TypeNeuralgiaAnimalsHumansMaleMiceRatsAdministration, OralDose-Response Relationship, DrugMice, Inbred C57BLomega-ConotoxinsRats, Inbred Lew

Stichwörter der Autor:innen

N‐type calcium channelPrialt®SNX 111d‐enantiomeric peptideneuropathic pain treatmentziconotideω‐Conotoxin MVIIA

Substanzen

CACNA1B protein, humanCalcium Channel BlockersCalcium Channels, N-Typeomega-Conotoxinsziconotide

Autor:innen und Institutionen

  • Institute of Biological Information Processing 7, Structural Biochemistry, Forschungszentrum Jülich GmbH, Jülich, Germany.
  • Institute of Neuroscience and Medicine, Medical Imaging Physics, Forschungszentrum Jülich GmbH, Jülich, Germany.
  • Institute of Neuro- und Sensory Physiology, Medical Faculty, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany.
  • Institute of Pharmaceutics and Biopharmaceutics, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany.
  • Institute for Pharmaceutical and Medicinal Chemistry, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
  • Institute of Biochemistry, Universität Leipzig, Leipzig, Germany.

ORCID-Profile: Holger Stark

Förderung

  • Forschungszentrum Jülich
  • Helmholtz Association

Zitieren

APA

Kutzsche, J., Guzman, G. A., Willuweit, A., Kletke, O., Wollert, E., Gering, I., Jürgens, D., Breitkreutz, J., Stark, H., Beck-Sickinger, A. G., Klöcker, N., Hidalgo, P., & Willbold, D. (2024). An orally available Ca v 2.2 calcium channel inhibitor for the treatment of neuropathic pain. British Journal of Pharmacology, 181(12), 1734-1756. https://doi.org/10.1111/bph.16309

Vancouver

Kutzsche J, Guzman GA, Willuweit A, Kletke O, Wollert E, Gering I, et al. An orally available Ca v 2.2 calcium channel inhibitor for the treatment of neuropathic pain. British Journal of Pharmacology. 2024;181(12):1734-1756. doi:10.1111/bph.16309

BibTeX
@article{Kutzsche2024,
  author = {Kutzsche, Janine and Guzman, Gustavo A and Willuweit, Antje and Kletke, Olaf and Wollert, Esther and Gering, Ian and Jürgens, Dagmar and Breitkreutz, Jörg and Stark, Holger and Beck-Sickinger, Annette G and Klöcker, Nikolaj and Hidalgo, Patricia and Willbold, Dieter},
  title = {An orally available Ca v 2.2 calcium channel inhibitor for the treatment of neuropathic pain},
  journal = {British Journal of Pharmacology},
  year = {2024},
  volume = {181},
  number = {12},
  pages = {1734--1756},
  doi = {10.1111/bph.16309}
}
Kostenlos starten →